natgillin/translations-raw huggingface dataset:
33 Overconsumption or incorrect use of medicinal products leads, moreover, to a waste of financial resources which is all the more damaging because the pharmaceutical sector generates considerable costs and must satisfy increasing needs, while the financial resources which may be made available for healthcare are not unlimited, whatever the mode of funding applied (see by analogy, with regard to hospital treatment, Case C-385/99 Müller-Fauré and van Riet [2003] ECR I-4509, paragraph 80, and Watts, paragraph 109). There is a direct link between those financial resources and the profits of businesses operating in the pharmaceutical sector because in most Member States the prescription of medicinal products is borne financially by the health insurance bodies concerned. 
33 Prekomjerna potrošnja ili nepravilna uporaba lijekova osim toga uzrokuje rasipanje financijskih resursa što je još štetnije jer farmaceutski sektor proizvodi visoke troškove i mora zadovoljiti rastuće potrebe, a istovremeno financijska sredstva koja su na raspolaganju za zaštitu zdravlja nisu neograničena, bez obzira na to koji se sustav financiranja primjenjuje (vidjeti analogno u vezi s bolničkim liječenjem presudu od 13. svibnja 2003. u predmetu Müller-Fauré i van Riet, C-385/99, Zb., str. I-4509., t. 80., i gore navedenu presudu Watts, t. 109.). U tom smislu valja naglasiti da između tih financijskih sredstava i profita gospodarskih subjekata koji djeluju u farmaceutskom sektoru postoji izravna veza, jer u većini država članica propisivanje lijekova ide na teret dotičnih tijela zdravstvenog osiguranja.
34 In the light of those risks to public health and to the financial balance of social security systems, the Member States may make persons entrusted with the retail supply of medicinal products subject to strict requirements, including as regards the way in which the products are marketed and the pursuit of profit. In particular, the Member States may restrict the retail sale of medicinal products, in principle, to pharmacists alone, because of the safeguards which pharmacists must provide and the information which they must be in a position to furnish to consumers (see, to this effect, Delattre, paragraph 56). 
34 S obzirom na te rizike za javno zdravlje i na financijsku ravnotežu sustava za zdravstveno osiguranje, države članice mogu uvjetovati da osobe odgovorne za distribuciju lijekova na malo podliježu strogim zahtjevima, uključujući posebno načine trgovanja i ostvarivanja dobiti. Konkretno, države članice mogu ograničiti prodaju lijekova na malo samo na farmaceute zbog jamstava koja moraju pružiti i informacija koje moraju biti u stanju dati potrošačima (vidjeti u tom smislu gore navedenu presudu Delattre, t. 56.).
35 In this connection, given the power accorded to the Member States to determine the level of protection of public health, it must be accepted that Member States may require that medicinal products be supplied by pharmacists enjoying genuine professional independence. They may also take measures which are capable of eliminating or reducing a risk that that independence will be prejudiced because such prejudice would be liable to affect the degree to which the provision of medicinal products to the public is reliable and of good quality. 
35 S tim u vezi, s obzirom na ovlasti dane državama članicama da odrede razinu zaštite javnog zdravlja, valja priznati da države članice mogu zahtijevati da lijekove distribuiraju farmaceuti koji su stvarno profesionalno neovisni. Države članice mogu također donijeti mjere kojima se može ukloniti ili smanjiti rizik zadiranja u tu neovisnost, jer bi takvo zadiranje moglo utjecati na razinu sigurnosti i kvalitete opskrbe stanovništva lijekovima.
37 It is undeniable that an operator having the status of pharmacist pursues, like other persons, the objective of making a profit. However, as a pharmacist by profession, he is presumed to operate the pharmacy not with a purely economic objective, but also from a professional viewpoint. His private interest connected with the making of a profit is thus tempered by his training, by his professional experience and by the responsibility which he owes, given that any breach of the rules of law or professional conduct undermines not only the value of his investment but also his own professional existence. 
37 Nije moguće negirati da voditelj koji ima status farmaceuta ima za cilj, kao što to imaju i druge osobe, ostvarivanje dobiti. Međutim, činjenica da se radi o farmaceutu po profesiji pretpostavlja da ljekarnu vodi ne samo iz gospodarskog interesa već i zbog profesionalnih razloga. Njegov privatni interes povezan s ostvarivanjem profita je stoga ublažen njegovom izobrazbom, profesionalnim iskustvom i odgovornošću koju ima, s obzirom da svako kršenje zakonskih propisa ili profesionalnog ponašanja ne samo da ugrožava vrijednost njegovog ulaganja već i njegovu vlastitu profesionalnu egzistenciju.
38 Unlike pharmacists, non-pharmacists by definition lack training, experience and responsibility equivalent to those of pharmacists. Accordingly, they do not provide the same safeguards as pharmacists. 
38 Za razliku od farmaceuta, osobe koje nisu farmaceuti po definiciji nemaju jednaku izobrazbu, iskustvo i odgovornost kao farmaceuti. U tim uvjetima valja utvrditi da ne pružaju jednaka jamstva kao farmaceuti.
40 It is therefore permissible for a Member State inter alia to assess, in the exercise of that discretion, whether such a risk exists in the case of manufacturers and wholesalers of pharmaceutical products on the ground that they might compromise the independence of employed pharmacists by encouraging them to promote the medicinal products which they produce or market themselves. Likewise, a Member State may determine whether operators lacking the status of pharmacist are liable to compromise the independence of employed pharmacists by encouraging them to sell off medicinal products which it is no longer profitable to keep in stock or whether those operators are liable to make reductions in operating costs which may affect the manner in which medicinal products are supplied at retail level. 
40 Osobito je zato državi članici dana mogućnost da u okviru navedene margine prosudbe procijeni postoji li takav rizik u vezi s proizvođačima i trgovcima farmaceutskih proizvoda na veliko zbog toga što bi mogli ugroziti neovisnost zaposlenih farmaceuta potičući ih da promoviraju lijekove koje sami proizvode ili stavljaju na tržište. Na isti način država članica može odrediti ugrožavaju li osobe koje nemaju status farmaceuta neovisnost zaposlenih farmaceuta potičući ih da prodaju lijekove čije držanje na zalihama više nije profitabilno i kolika je odgovornost tih voditelja kad smanjuju operativne troškove koji bi mogli utjecati na način distribucije lijekova na malo.
"42 As to those submissions, it is apparent from the Court’s case-law that national legislation is appropriate for securing attainment of the objective relied upon only if it genuinely reflects a concern to attain that objective in a consistent and systematic manner (see Joined Cases C-338/04, C-359/04 and C-360/04 Placanica and Others [2007] ECR I-1891, paragraphs 53 and 58; Case C-500/06 Corporación Dermoestética [2008] ECR I-0000, paragraphs 39 and 40; and Hartlauer, paragraph 55)." 
"42 U vezi s tim iz sudske prakse Suda proizlazi da nacionalno uređenje može jamčiti ostvarenje navedenog cilja samo ako zaista dosljedno i sustavno odražava nastojanje za postizanjem tog cilja (vidjeti presude od 6. ožujka 2007., Placanica i drugi, C-338/04, C-359/04 i C-360/04, Zb., str. I-1891., t. 53. i 58.; od 17. srpnja 2008., Corporación Dermoestética, C-500/06, Zb., str. I-5785., t. 39. i 40.; i gore navedenu presudu Hartlauer, t. 55.)."
45 However, this exception proves justified having regard to protection of the legitimate property rights and interests of the members of the deceased pharmacist’s family. It must be found that the Member States may take the view that the interests of a pharmacist’s heirs are not such as to jeopardise the requirements and guarantees flowing from their respective legal systems which operators who have the status of pharmacist must meet. In this context, account is to be taken especially of the fact that throughout the transitional period a qualified pharmacist must be responsible for operating the inherited pharmacy. Therefore, the heirs cannot, in this specific context, be equated with other operators who do not have the status of pharmacist. 
45 Međutim, taj se izuzetak pokazuje opravdanim s obzirom na zaštitu legitimnih vlasničkih prava i interesa članova obitelji pokojnog farmaceuta. U vezi s tim valja utvrditi da države članice mogu smatrati da interesi nasljednika nisu takvi da ugrožavaju zahtjeve i jamstva iz njihovih pravnih sustava koje moraju ispunjavati voditelji koji imaju status farmaceuta. U tom kontekstu potrebno je uzeti u obzir činjenicu da tijekom prijelaznog razdoblja za vođenje naslijeđene ljekarne mora biti odgovoran kvalificirani farmaceut. Stoga nasljednici u tom konkretnom kontekstu ne mogu biti izjednačeni s drugim voditeljima koji nemaju status farmaceuta.
48 Next, nor can such a risk result from the fact that hospitals may operate internal pharmacies. The latter are intended to provide medicinal products not to persons outside those hospitals but to the hospitals in which they are established. Thus, hospitals which operate such pharmacies are not, in principle, capable of affecting the general level of reliability and quality in the provision of medicinal products to the public as a whole. Furthermore, having regard to the fact that those hospitals provide medical care, there are no grounds for assuming that they would have an interest in making a profit to the detriment of the patients for whom the medicinal products of the pharmacies which they house are intended. 
48 Nadalje takav rizik ne može proizlaziti ni iz činjenice da bolnice mogu voditi interne ljekarne. One u stvari nisu namijenjene osiguravanju opskrbe lijekovima osobama izvan tih bolnica, već bolnicama u kojima su otvorene. Stoga bolnice koje vode takve ljekarne ne mogu načelno utjecati na opću razinu sigurnosti i kvalitete opskrbe cjelokupnog stanovništva lijekovima. Osim toga, uzimajući u obzir činjenicu da te bolnice pružaju zdravstvenu skrb, nema razloga za pretpostaviti da bi one imale interes ostvarivanja dobiti na štetu pacijenata kojima su namijenjeni lijekovi iz ljekarni otvorenih u tim bolnicama.
49 Finally, although the national legislation allows pharmacists to operate up to three branches of a single pharmacy, such a possibility is subject to a number of conditions which are intended to safeguard public health requirements. First of all, the pharmacist concerned is himself responsible for the branches’ operation and he therefore determines their general commercial policy. Those branches are thus also presumed to be operated from a professional viewpoint, the private interest connected with the making of a profit being tempered to the same extent as in the case of the operation of pharmacies which are not branches. Next, those branches must be located within a specified geographical radius in order to ensure a sufficient presence in the branches of the pharmacist operating them and actual supervision by him. Last, the pharmacist operating the branches must designate, for each branch, a responsible pharmacist, who must ensure that legal obligations are complied with and that the management of the branch concerned conforms to the general commercial policy determined by the pharmacist operating the branches. 
49 Naposljetku, iako nacionalni propis dozvoljava farmaceutima vođenje do najviše tri podružnice iste ljekarne, takva mogućnost podliježe nizu uvjeta koji su namijenjeni zaštiti zahtjeva u vezi s javnim zdravljem. Kao prvo, dotični farmaceut je osobno odgovoran za poslovanje podružnica i on stoga određuje njihovu opću tržišnu politiku. Smatra se stoga da se navedene podružnice vode s profesionalnog stajališta na način da je privatni interes povezan s ostvarivanjem dobiti ublažen u istoj mjeri kao i u slučaju vođenja ljekarni koje nisu podružnice. Nadalje, te podružnice moraju biti smještene u određenom geografskom radijusu kako bi se osigurala dovoljna prisutnost farmaceuta koji ih vodi i njegov učinkovit nadzor. Konačno, farmaceut koji upravlja podružnicama mora za svaku podružnicu odrediti odgovornog farmaceuta koji mora osigurati da se poštuju zakonske obveze i sukladnost vođenja dotične podružnice s općom tržišnom politikom koju je odredio farmaceut voditelj.
55 The Commission has not put forward, apart from general considerations, anything to show what the specific system would be that would be capable of ensuring – with the same effectiveness as the rule excluding non-pharmacists – that those legislative rules are observed in practice notwithstanding the considerations set out in the previous paragraph of the present judgment. 
55 Komisija nije iznijela nijedan element, osim općih očitovanja, koji bi dokazao kakav bi to konkretan sustav bio u stanju osigurati – na jednako učinkovit način kao što to osigurava pravilo o isključenju osoba koje nisu farmaceuti – da se spomenuta zakonska pravila ne bi u praksi kršila, bez obzira na razmatranja iznesena u prethodnoj točki ove presude.
56 Nor, contrary to DocMorris’s and the Commission’s submissions, can the risks to the independence of the profession of pharmacist be excluded with the same effectiveness by the means consisting in the imposition of an obligation to take out insurance, such as insurance for vicarious civil liability. While that measure might enable the patient to obtain financial reparation for any harm suffered by him, it operates after the event and would be less effective than the rule excluding non-pharmacists in that it would not in any way prevent the operator concerned from exerting influence over the employed pharmacists. 
56 Osim toga u suprotnosti s tvrdnjama društva DocMorris’s i Komisije rizik za profesionalnu neovisnost farmaceuta ne bi bilo moguće jednako učinkovito isključiti na način koji bi uključivao nametanje obveze sklapanja osiguranja, kao što je osiguranje građanske odgovornosti za drugog. Iako bi takva mjera mogla omogućiti pacijentu da dobije financijsku odštetu za pretrpljenu štetu, ona bi nastupila naknadno i bila bi manje učinkovita od pravila o isključenju osoba koje nisu farmaceuti u tom smislu da se dotičnog voditelja ni na koji način ne bi moglo spriječiti da utječe na zaposlene farmaceute.
59 This conclusion is not called into question by the judgment in Case C-140/03 Commission v Greece [2005] ECR I-3177, upon which Saarland, the Ministry, DocMorris and the Commission rely, where the Court ruled that the Hellenic Republic had failed to fulfil its obligations under Articles 43 EC and 48 EC by enacting and maintaining in force national provisions under which the establishment by a legal person of an optician’s shop was subject inter alia to the condition that authorisation for the establishment and operation of that shop had to have been granted to a recognised optician who was a natural person and the person holding the authorisation to operate the shop had to hold at least 50% of the company’s share capital and participate at least to that extent in the profits and losses of the company. 
59 Taj se zaključak ne dovodi u pitanje presudom od 21. travnja 2005., Komisija/Grčka, C-140/03, Zb., str. I-3177., na koju se pozivaju savezna država Saarland, Ministerium, tvrtka DocMorris i Komisija, u kojoj je Sud presudio da Helenska Republika nije ispunila svoje obveze u skladu s člancima 43. UEZ-a i 48. UEZ-a jer je donijela i zadržala na snazi nacionalne odredbe koje mogućnost pravne osobe da otvori optičarsku radnju ograničavaju osobito uvjetom da se dozvola za otvaranje i vođenje takve radnje izdaje ovlaštenom optičaru kao fizičkoj osobi i da ta osoba koja ima dozvolu posjeduje najmanje 50 % udjela u kapitalu društva i najmanje u tom opsegu sudjeluje u dobicima i gubicima društva.
60 Given the particular nature of medicinal products and of the medicinal-product market, and as Community law currently stands, the Court’s findings in Commission v Greece cannot be transposed to the field of the retail supply of medicinal products. Unlike optical products, medicinal products prescribed or used for therapeutic reasons may none the less prove seriously harmful to health if they are consumed unnecessarily or incorrectly, without the consumer being in a position to realise that when they are administered. Furthermore, a medically unjustified sale of medicinal products leads to a waste of public financial resources which is not comparable to that resulting from unjustified sales of optical products. 
60 S obzirom na posebnu narav lijekova kao i tržišta lijekova te trenutačnog stupnja prava Zajednice, nalazi Suda u gore navedenoj presudi Komisija/Grčka ne mogu se prenijeti na područje distribucije lijekova na malo. Za razliku od optičarskih pomagala, lijekovi koji se propisuju i koriste u terapeutske svrhe mogu unatoč svemu ozbiljno naštetiti zdravlju ako se uzimaju nepotrebno ili neispravno, a da potrošač nema mogućnost da toga postane svjestan prilikom izdavanja lijeka. Osim toga zdravstveno neutemeljena prodaja lijekova dovodi do rasipanja javnih financijskih sredstava koje se ne može usporediti s rasipanjem uzrokovanim neopravdanom prodajom optičarskih pomagala.
63 Since these proceedings are, for the parties to the main proceedings, a step in the actions pending before the national court, the decision on costs is a matter for that court. Costs incurred in submitting observations to the Court, other than the costs of those parties, are not recoverable. 
63 Budući da ovaj postupak ima značaj prethodnog pitanja za stranke glavnog postupka pred sudom koji je uputio zahtjev, na tom je sudu da odluči o troškovima postupka. Troškovi podnošenja očitovanja Sudu, koji nisu troškovi spomenutih stranaka, ne nadoknađuju se.
Articles 43 EC and 48 EC do not preclude national legislation, such as that at issue in the main actions, which prevents persons not having the status of pharmacist from owning and operating pharmacies. 
Člancima 43. UEZ-a i 48. UEZ-a nije protivan nacionalni propis, kao što je onaj u predmetu u glavnom postupku, koji osobe koje nemaju status farmaceuta sprečava da posjeduju i vode ljekarne.
19 November 2009 (*) 
19. studenoga 2009.*
(Air transport – Regulation (EC) No 261/2004 – Article 2(l) and Articles 5, 6 and 7 – Concept of flight ‘delay’ and ‘cancellation’ – Right to compensation in the event of delay – Concept of ‘extraordinary circumstances’) 
„Zračni promet – Uredba (EZ) br. 261/2004 – članak 2. točka (l) i članci 5., 6. i 7. – Pojmovi ,kašnjenje’ i ,otkazivanje’ leta – Pravo na odštetu u slučaju kašnjenja – Pojam ,izvanredne okolnosti’”
In Joined Cases C-402/07 and C-432/07, 
U spojenim predmetima C-402/07 i C-432/07,
REFERENCES for a preliminary ruling under Article 234 EC from the Bundesgerichtshof (Germany) and the Handelsgericht Wien (Austria) made by decisions of 17 July and 26 June 2007, received at the Court on 30 August and 18 September 2007 respectively, in the proceedings 
povodom zahtjeva za prethodnu odluku na temelju članka 234. UEZ-a, koji su uputili Bundesgerichtshof (Njemačka) i Handelsgericht Wien (Austrija), odlukama od 17. srpnja i 26. lipnja 2007., koje je Sud zaprimio 30. kolovoza i 18. rujna 2007., u postupcima
Christopher Sturgeon, 
Christopher Sturgeon,
Gabriel Sturgeon, 
Gabriel Sturgeon,
Alana Sturgeon 
Alana Sturgeon
v Condor Flugdienst GmbH (C-402/07), 
protiv Condor Flugdienst GmbH (C-402/07),
Stefan Böck, 
Stefan Böck,
Cornelia Lepuschitz 
Cornelia Lepuschitz
v Air France SA (C-432/07), 
protiv Air France SA (C-432/07),
composed of K. Lenaerts, President of the Third Chamber, acting for the President of the Fourth Chamber, R. Silva de Lapuerta, E. Juhász, G. Arestis and J. Malenovský (Rapporteur), Judges, 
u sastavu: K. Lenaerts, predsjednik trećeg vijeća, u funkciji predsjednika četvrtog vijeća, R. Silva de Lapuerta, E. Juhász, G. Arestis i J. Malenovský (izvjestitelj), suci,
having regard to the written procedure and further to the hearing on 24 September 2008, 
uzimajući u obzir pisani postupak i nakon rasprave održane 24. rujna 2008.,
– C. Sturgeon, G. Sturgeon and A. Sturgeon, by R. Schmid, Rechtsanwalt, 
– za C. Sturgeon, G. Sturgeon i A. Sturgeon, R. Schmid, Rechtsanwalt,
– S. Böck and C. Lepuschitz, by M. Wukoschitz, Rechtsanwalt, 
– za S. Böck i C. Lepuschitz, M. Wukoschitz, Rechtsanwalt,
– Condor Flugdienst GmbH, by C. Marko and C. Döring, Rechtsanwälte, 
– za Condor Flugdienst GmbH, C. Marko i C. Döring, Rechtsanwälte,
– Air France SA, by O. Borodajkewycz, Rechtsanwalt, 
– za Air France SA, O. Borodajkewycz, Rechtsanwalt,
– the Greek Government, by S. Chala and D. Tsagkaraki, acting as Agents, 
– za grčku vladu, S. Chala i D. Tsagkaraki, u svojstvu agenata,
– the French Government, by G. de Bergues and A. Hare, acting as Agents, 
– za francusku vladu, G. de Bergues i A. Hare, u svojstvu agenata,
– the Italian Government, by I.M. Braguglia, acting as Agent, and W. Ferrante, avvocato dello Stato, 
– za talijansku vladu, I. M. Braguglia, u svojstvu agenta, uz asistenciju W. Ferrante, avvocato dello Stato,
– the Polish Government, by M. Dowgielewicz, acting as Agent, 
– za poljsku vladu, M. Dowgielewicz, u svojstvu agenta,
– the Swedish Government, by A. Falk, acting as Agent, 
– za švedsku vladu, A. Falk, u svojstvu agenta,
– the United Kingdom Government, by T. Harris, acting as Agent, and D. Beard, Barrister, 
– za vladu Ujedinjene Kraljevine, T. Harris, u svojstvu agenta, uz asistenciju D. Bearda, barrister,
– the Commission of the European Communities, by R. Vidal-Puig and P. Dejmek, acting as Agents, 
– za Komisiju Europskih zajednica, R. Vidal-Puig i P. Dejmek, u svojstvu agenata,
after hearing the Opinion of the Advocate General at the sitting on 2 July 2009, 
saslušavši mišljenje nezavisne odvjetnice na raspravi održanoj 2. srpnja 2009.,
1 These references for a preliminary ruling concern the interpretation of Articles 2(l), 5, 6 and 7 of Regulation (EC) No 261/2004 of the European Parliament and of the Council of 11 February 2004 establishing common rules on compensation and assistance to passengers in the event of denied boarding and of cancellation or long delay of flights, and repealing Regulation (EEC) No 295/91 (OJ 2004 L 46, p. 1). 
1 Zahtjevi za prethodnu odluku odnose se na tumačenje članka 2. točke (l) i članaka 5., 6. i 7. Uredbe (EZ) br. 261/2004 Europskog parlamenta i Vijeća od 11. veljače 2004. o utvrđivanju općih pravila odštete i pomoći putnicima u slučaju uskraćenog ukrcaja i otkazivanja ili dužeg kašnjenja leta u polasku te o stavljanju izvan snage Uredbe (EEZ) br. 295/91 (SL L 46, str. 1.) (SL, posebno izdanje na hrvatskom jeziku, poglavlje 7., svezak 26., str. 21.).
2 The references were made in proceedings between (i) Mr Sturgeon and his family (‘the Sturgeons’) and Condor Flugdienst GmbH (‘Condor’) (C-402/07) and (ii) Mr Bock and Ms Lepuschitz and Air France SA (‘Air France’) (C-432/07), concerning the refusal of those airlines to pay compensation to the passengers concerned, whose arrival at the airport of destination was delayed by 25 and 22 hours respectively in relation to the scheduled arrival time. 
2 Zahtjevi su upućeni u okviru sporova između C. Sturgeona i njegove obitelji (dalje u tekstu: obitelj Sturgeon), s jedne strane, i zračnog prijevoznika Condor Flugdienst GmbH (dalje u tekstu: Condor), s druge strane, (C-402/07), te između S. Böck i C. Lepuschitz, s jedne strane, i zračnog prijevoznika Air France SA (dalje u tekstu: Air France), s druge strane, (C-432/07),u vezi s odbijanjem tih zračnih prijevoznika da plate odštetu dotičnim putnicima čiji je dolazak u odredišnu zračnu luku kasnio 25 odnosno 22 sata u odnosu na predviđeno vrijeme dolaska.
3 Recitals 1 to 4 in the preamble to Regulation No 261/2004 state: 
3 Uvodne izjave od 1. do 4. Uredbe br. 261/2004 glase: